OCT Forges Partnership with Voisin Consulting Life Sciences
Oxford Cannabinoid Technologies Holdings plc (“OCTP”), the UK-based pharmaceutical company focussed on developing cannabinoid-based prescription medicines approved by regulatory agencies, is delighted today to announce that it has entered into a new partnership with Voisin Consulting Life Sciences (“VCLS”), an international HealthTech and product consultancy which has offices in the UK, Europe, US and India. VCLS has expertise in medical devices, cannabinoids, neurological disorders and addiction, providing services that will:
support and develop a regulatory strategy and roadmap for the UK and the US markets as a priority and consider potential subsequent development in the EU;
provide a high-level nonclinical gap analysis of OCTP’s development plan to support First Time in Humans (FTiH) clinical trials; and
provide a high-level review of OCTP’s clinical development plan in relation to FTiH studies planned in patients;
This exciting partnership will provide significant support for OCTP’s development of its lead drug candidate, OCT461201, in the areas of post-herpetic neuralgia and IBS related visceral pain. OCTP has previously engaged VCLS on regulatory matters relating to the development of its phytocannabinoid drug candidate.
Dr John Lucas, Chief Executive Officer of OCTP, said: “we are delighted to continue to partner with Voisin Consulting Life Sciences in our quest to deliver life-changing therapies for severe pain. OCTP, which recently listed on the London Stock Exchange (LSE: OCTP), wants its innovative strategy to have the necessary depth in strength and quality which is crucial to deliver a much-needed product that is both safe and efficacious. Our management team is determined to do the right thing for its patients, and we believe that a consultancy firm like VCLS can provide us with best-in-class support. As a consequence of our early discussions with the VCLS team, it became clear that their expertise, knowledge, and quality meant they were the partners we were looking for.”
Emmanuelle M Voisin, Founder and CEO of Voisin Consulting Life Sciences, said: “we are thrilled to be partnering with Oxford Cannabinoid Technologies at this important stage, to support it on its exciting journey to become the global leader in developing cannabinoid-based prescription medicines. I am delighted that OCTP has chosen Voisin Consulting Life Sciences to facilitate its delivery of innovative, life-changing pain medication.”
